PBYI Puma Biotechnology, Inc. Stock Quote

PBYI [NASD]

Index	-	P/E	-	EPS (ttm)	-1.20	Insider Own	15.00%	Shs Outstand	42.21M	Perf Week	-1.55%
Market Cap	85.47M	Forward P/E	-	EPS next Y	-0.08	Insider Trans	-1.12%	Shs Float	38.63M	Perf Month	-27.92%
Income	-49.00M	PEG	-	EPS next Q	-0.01	Inst Own	68.40%	Short Float	8.62%	Perf Quarter	-13.18%
Sales	200.70M	P/S	0.43	EPS this Y	52.70%	Inst Trans	-0.21%	Short Ratio	7.37	Perf Half Y	-39.94%
Book/sh	0.17	P/B	11.24	EPS next Y	175.00%	ROA	-21.40%	Target Price	6.40	Perf Year	-81.44%
Cash/sh	1.65	P/C	1.16	EPS next 5Y	-	ROE	-842.40%	52W Range	1.60 - 11.95	Perf YTD	-37.17%
Dividend	-	P/FCF	-	EPS past 5Y	38.70%	ROI	-17.70%	52W High	-84.02%	Beta	1.07
Dividend %	-	Quick Ratio	1.50	Sales past 5Y	-	Gross Margin	77.60%	52W Low	19.37%	ATR	0.18
Employees	196	Current Ratio	1.60	Sales Q/Q	-53.50%	Oper. Margin	-18.50%	RSI (14)	40.35	Volatility	7.71% 9.88%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-120.00%	Profit Margin	-24.40%	Rel Volume	0.57	Prev Close	1.84
Shortable	Yes	LT Debt/Eq	13.72	Earnings	May 05 AMC	Payout	-	Avg Volume	451.69K	Price	1.91
Recom	2.80	SMA20	-6.95%	SMA50	-25.88%	SMA200	-51.85%	Volume	258,529	Change	3.80%

Sep-28-21

Upgrade

Citigroup

Neutral → Buy

$11

Jun-25-20

Resumed

BofA/Merrill

Underperform

Oct-08-19

Downgrade

Goldman

Neutral → Sell

$24 → $8

May-10-19

Downgrade

Citigroup

Buy → Neutral

$24

May-10-19

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$57 → $20

Jan-17-19

Initiated

Leerink Partners

Mkt Perform

$21

Jan-03-19

Downgrade

Guggenheim

Buy → Neutral

Nov-19-18

Upgrade

Goldman

Sell → Neutral

Nov-02-18

Downgrade

JP Morgan

Neutral → Underweight

Nov-02-18

Downgrade

BofA/Merrill

Buy → Underperform

Oct-01-18

Initiated

Cantor Fitzgerald

Overweight

$75

Sep-17-18

Initiated

Goldman

Sell

$42

May-11-18

Reiterated

Stifel

Buy

$95 → $87

Nov-10-17

Reiterated

RBC Capital Mkts

Sector Perform

$92 → $108

Nov-10-17

Reiterated

Citigroup

Buy

$156 → $164

Oct-02-17

Reiterated

Stifel

Buy

$110 → $130

Sep-11-17

Reiterated

Credit Suisse

Outperform

$118 → $136

Jul-10-17

Resumed

Leerink Partners

Outperform

$115

Jun-06-17

Reiterated

RBC Capital Mkts

Sector Perform

$60 → $88

May-25-17

Reiterated

RBC Capital Mkts

Sector Perform

$40 → $60

May-11-22 05:31PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire -9.89%
May-06-22 11:01AM	Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y Zacks -11.38%
May-05-22 06:05PM	Puma Biotech (PBYI) Reports Q1 Loss, Misses Revenue Estimates Zacks -8.94%
04:05PM	Puma Biotechnology Reports First Quarter 2022 Financial Results Business Wire
May-04-22 05:35PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates Zacks
Apr-28-22 03:02PM	Puma Biotech (PBYI) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-27-22 04:15PM	Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting Business Wire -5.66%
Apr-21-22 04:11PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Business Wire
Apr-05-22 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-10-22 08:30AM	Puma Biotechnology Announces $10 Million Private Placement Business Wire
Mar-07-22 09:00AM	Puma Biotechnology to Participate in Breast Cancer Panel at Cowens Annual Health Care Conference Business Wire
Mar-05-22 06:13AM	Market Sentiment Around Loss-Making Puma Biotechnology, Inc. (NASDAQ:PBYI) Simply Wall St.
Mar-04-22 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire +8.15%
Mar-03-22 06:05PM	Puma Biotech (PBYI) Q4 Earnings and Revenues Surpass Estimates Zacks
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Business Wire
Feb-17-22 03:02PM	Will Puma Biotech (PBYI) Report Negative Q4 Earnings? What You Should Know Zacks -5.63%
Feb-16-22 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results Business Wire
Feb-03-22 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-20-22 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-12-22 04:10PM	Puma Biotechnologys NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer Business Wire
Jan-10-22 09:38AM	Patriot Financial Group Insurance Agency, LLC Buys Schwab U.S. Tips ETF, iShares Core U.S. ... GuruFocus.com
07:00AM	Puma Biotechnology Releases Updated Corporate Presentation Business Wire
Jan-04-22 04:14PM	Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference Business Wire
Dec-10-21 12:05PM	Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting Business Wire -8.95%
Dec-03-21 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
11:35AM	Do Options Traders Know Something About Puma (PBYI) Stock We Don't? Zacks
Nov-23-21 04:07PM	Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib) Business Wire
Nov-22-21 06:48AM	Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial Benzinga -7.02%
Nov-20-21 11:40AM	Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting Business Wire
Nov-19-21 09:05AM	Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) Business Wire
Nov-18-21 09:55AM	What Type Of Shareholders Own The Most Number of Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares? Simply Wall St.
Nov-05-21 10:31AM	Puma (PBYI) Misses on Q3 Earnings, Cuts Sales View, Stock Down Zacks -37.25%
Nov-04-21 06:45PM	Puma Biotech (PBYI) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:07PM	Puma Biotechnology Reports Third Quarter 2021 Financial Results Business Wire
Oct-28-21 03:05PM	Will Puma Biotech (PBYI) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-06-21 05:01PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-21-21 04:10PM	Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference Business Wire
Sep-07-21 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
04:15PM	Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire
Aug-06-21 04:50PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
12:27PM	Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut Zacks
Aug-05-21 08:25PM	Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:07PM	Puma Biotechnology Reports Second Quarter 2021 Financial Results Business Wire
Jul-30-21 10:36AM	Puma Biotechnology Inc (PBYI): Are Hedge Funds Right About This Stock? Insider Monkey
Jul-29-21 03:05PM	Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline Zacks
Jul-26-21 08:33AM	Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital Business Wire
Jul-22-21 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Business Wire
Jul-06-21 08:00AM	Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer GlobeNewswire
Jul-02-21 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire -6.07%
Jul-01-21 08:35AM	FDA Approves Dose Escalation Label Update for Puma Biotechnologys NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer Business Wire
Jun-25-21 04:33AM	We Think Puma Biotechnology (NASDAQ:PBYI) Is Taking Some Risk With Its Debt Simply Wall St.
Jun-19-21 03:30AM	Did Business Growth Power Boyd Group Services' (TSE:BYD) Share Price Gain of 201%? Simply Wall St.
Jun-04-21 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
09:05AM	Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting Business Wire
09:04AM	Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting Business Wire
09:03AM	Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting Business Wire
May-19-21 05:05PM	Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting Business Wire
May-07-21 08:52AM	Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View Zacks
May-06-21 07:05PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Beat Estimates Zacks
04:05PM	Puma Biotechnology Reports First Quarter 2021 Financial Results Business Wire
02:45PM	Puma Biotechnology, Inc. to Host Earnings Call ACCESSWIRE
May-04-21 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-29-21 05:03PM	Puma Biotech (PBYI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Apr-26-21 09:04AM	When Will Puma Biotechnology, Inc. (NASDAQ:PBYI) Turn A Profit? Simply Wall St.
Apr-22-21 04:15PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Business Wire
Apr-13-21 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-27-21 11:31AM	Puma Biotech (PBYI) Down 6.3% Since Last Earnings Report: Can It Rebound? Zacks
Mar-09-21 05:26AM	The wild ride that made Rudy Giuliani, 'Kraken' lawyer Sidney Powell, and Fox News targets in the mother of all defamation cases Yahoo Finance +6.01%
Mar-08-21 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-05-21 01:15AM	Polyphor Announces Financial Results for the Full-Year 2020 GlobeNewswire
Mar-04-21 04:15PM	Puma Biotechnology to Present at the Barclays Global Healthcare Conference Business Wire
Mar-02-21 04:20PM	Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Feb-26-21 10:10AM	Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall Zacks -5.59%
08:16AM	The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga
Feb-25-21 04:07PM	Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China Business Wire -6.72%
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Business Wire
02:30PM	Puma Biotechnology, Inc. to Host Earnings Call ACCESSWIRE
Feb-11-21 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results Business Wire
Feb-09-21 04:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.38%
Jan-29-21 08:00AM	Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020 Business Wire
Jan-26-21 04:25AM	Puma Biotechnology's (NASDAQ:PBYI) Shareholders Are Down 82% On Their Shares Simply Wall St.
Jan-19-21 09:00AM	Puma Biotechnology to Present at the B. Riley Oncology Investor Conference Business Wire
Jan-15-21 08:03AM	Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT "Basket" Trial of Neratinib at ASCO GI Business Wire
Jan-05-21 04:15PM	Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference Business Wire
Jan-04-21 04:15PM	Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference Business Wire
Dec-16-20 05:22PM	Is PBYI A Good Stock To Buy Now? Insider Monkey
Dec-11-20 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
02:00PM	Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS Business Wire
Dec-09-20 07:31PM	Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS Business Wire -7.16%
05:03PM	Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 Business Wire
Dec-05-20 11:32AM	Why Is Puma Biotech (PBYI) Up 36% Since Last Earnings Report? Zacks
Dec-02-20 08:30AM	Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted Business Wire
Nov-17-20 04:15PM	Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) Business Wire
Nov-09-20 12:11PM	Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut Zacks +7.84%
06:42AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Just Reported Earnings, And Analysts Cut Their Target Price Simply Wall St.
Nov-06-20 04:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire -8.15%
09:31AM	Puma Biotechnology Inc (PBYI) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 05:35PM	Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:07PM	Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer Business Wire
04:05PM	Puma Biotechnology Reports Third Quarter 2020 Financial Results Business Wire

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HUNT DOUGLAS M	See Remarks	May 03	Sale	2.31	438	1,012	81,900	May 05 05:36 PM
NOUGUES MAXIMO F	Chief Financial Officer	May 03	Sale	2.34	165	386	121,228	May 04 06:46 PM
NOUGUES MAXIMO F	Chief Financial Officer	May 03	Sale	2.34	165	386	121,228	May 04 06:44 PM
NOUGUES MAXIMO F	Chief Financial Officer	May 03	Sale	2.34	165	386	121,228	May 04 06:43 PM
AUERBACH ALAN H	President and CEO	May 03	Sale	2.32	1,263	2,930	6,345,292	May 04 06:37 PM
HUNT DOUGLAS M	See Remarks	Apr 04	Sale	3.08	413	1,271	82,338	Apr 05 04:55 PM
NOUGUES MAXIMO F	Chief Financial Officer	Apr 04	Sale	3.08	206	634	121,393	Apr 05 04:52 PM
AUERBACH ALAN H	President and CEO	Apr 04	Sale	3.08	1,198	3,687	6,346,555	Apr 05 05:41 PM
MILLER MICHAEL PATRICK	Director	Mar 16	Sale	2.80	25,653	71,792	52,858	Mar 17 04:33 PM
NOUGUES MAXIMO F	Chief Financial Officer	Mar 02	Sale	2.26	169	382	59,423	Mar 04 05:14 PM
HUNT DOUGLAS M	See Remarks	Mar 02	Sale	2.26	446	1,009	60,104	Mar 04 05:11 PM
AUERBACH ALAN H	President and CEO	Mar 02	Sale	2.26	1,294	2,919	4,386,815	Mar 04 05:07 PM
HUNT DOUGLAS M	See Remarks	Feb 02	Sale	2.47	533	1,317	60,550	Feb 03 07:38 PM
NOUGUES MAXIMO F	Chief Financial Officer	Feb 02	Sale	2.48	199	494	59,592	Feb 03 05:34 PM
AUERBACH ALAN H	President and CEO	Feb 02	Sale	2.46	1,316	3,239	4,388,109	Feb 03 05:29 PM
AUERBACH ALAN H	President and CEO	Jan 03	Sale	3.19	22,875	72,923	4,389,425	Jan 05 05:12 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 03	Sale	3.19	7,484	23,871	59,791	Jan 05 05:04 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jan 03	Sale	3.20	4,727	15,121	31,342	Jan 05 08:32 PM
HUNT DOUGLAS M	See Remarks	Jan 03	Sale	3.21	3,707	11,890	61,083	Jan 05 06:03 PM
Wong Alvin F	Chief Scientific Officer	Dec 02	Sale	2.91	1,131	3,294	17,152	Dec 06 06:55 PM
HUNT DOUGLAS M	See Remarks	Dec 02	Sale	2.90	441	1,279	64,790	Dec 06 08:33 PM
NOUGUES MAXIMO F	Chief Financial Officer	Dec 02	Sale	2.95	162	478	67,275	Dec 06 06:37 PM
AUERBACH ALAN H	President and CEO	Dec 02	Sale	2.90	1,837	5,327	4,412,300	Dec 06 06:31 PM
NOUGUES MAXIMO F	Chief Financial Officer	Nov 02	Sale	5.67	156	885	67,437	Nov 03 06:22 PM
HUNT DOUGLAS M	See Remarks	Nov 02	Sale	5.64	427	2,409	65,231	Nov 03 06:20 PM
AUERBACH ALAN H	PRESIDENT AND CEO	Nov 02	Sale	5.63	1,795	10,112	4,414,137	Nov 03 06:17 PM
NOUGUES MAXIMO F	Chief Financial Officer	Oct 04	Sale	6.20	161	998	67,593	Oct 06 05:20 PM
HUNT DOUGLAS M	See Remarks	Oct 04	Sale	6.15	443	2,726	65,658	Oct 06 05:15 PM
AUERBACH ALAN H	President and CEO	Oct 04	Sale	6.15	1,858	11,433	4,415,932	Oct 06 05:04 PM
NOUGUES MAXIMO F	Chief Financial Officer	Sep 02	Sale	7.51	155	1,164	67,754	Sep 03 07:40 PM
HUNT DOUGLAS M	See Remarks	Sep 02	Sale	7.52	422	3,174	66,101	Sep 07 03:36 PM
AUERBACH ALAN H	PRESIDENT AND CEO	Sep 02	Sale	7.60	1,764	13,403	4,417,790	Sep 03 09:27 PM
NOUGUES MAXIMO F	Chief Financial Officer	Aug 02	Sale	7.54	154	1,161	67,909	Aug 03 05:52 PM
HUNT DOUGLAS M	See Remarks	Aug 02	Sale	7.53	420	3,161	66,523	Aug 03 05:49 PM
AUERBACH ALAN H	PRESIDENT AND CEO	Aug 02	Sale	7.53	1,764	13,286	4,419,554	Aug 03 05:45 PM
AUERBACH ALAN H	PRESIDENT AND CEO	Jul 02	Sale	8.84	5,332	47,121	4,421,318	Jul 06 07:42 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 02	Sale	9.26	155	1,435	68,063	Jul 06 05:43 PM
HUNT DOUGLAS M	See Remarks	Jul 02	Sale	9.15	1,016	9,298	66,943	Jul 06 05:40 PM
Senderowicz Adrian	Director	Jun 11	Sale	11.17	40,993	457,757	0	Jun 15 06:14 PM
MOYES JAY M	Director	Jun 10	Sale	11.36	25,248	286,860	6,322	Jun 11 05:36 PM
Miller Ann Calby	Director	Jun 10	Sale	11.43	12,874	147,156	12,874	Jun 11 04:59 PM
WILSON TROY EDWARD	Director	Jun 10	Sale	11.36	25,748	292,433	350	Jun 11 07:30 PM
HUNT DOUGLAS M	See Remarks	Jun 02	Sale	10.77	416	4,481	67,959	Jun 04 04:53 PM
AUERBACH ALAN H	PRESIDENT AND CEO	Jun 02	Sale	10.74	1,757	18,877	4,426,650	Jun 04 04:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience